(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Jae-Lyun Lee discussing updated data of pembrolizumab monotherapy among patients with non-clear cell renal cell carcinoma (RCC) from Cohort B of the KEYNOTE-427 trial. Approved therapies for non-clear cell RCC are needed because most clinical trials have focused on the more prevalent clear cell RCC. The open-label, single-arm, phase II KEYNOTE-427 study was designed to investigate the efficacy and safety of monotherapy with pembrolizumab in treatment-naïve patients with either clear-cell RCC (cohort A) or non-clear cell RCC (Cohort B). In cohort B, after >2 years of follow-up, the objective response rate (ORR) was 26.7%, median overall survival (OS) was 28.9 months, and the median duration of response was 29.0 months in the overall population.1 At the 2021 ESMO congress, Dr. Lee and colleagues presented updated efficacy and safety results after a minimum of 34 months of follow-up for patients with non-clear cell RCC (Cohort B).

X